Quolet announces completion of Phase 1 healthy volunteer study evaluating the safety and bioavailability of Cannabidiol in a novel formulation intended for treatment of various neurological and psychiatric diseases

BOSTON–(BUSINESS WIRE)–#ANXIETY—Quolet, a private clinical stage biopharmaceutical company, is announcing the completion of a Phase 1 healthy volunteer study evaluating pure Cannabidiol (CBD) (clinicaltrials.gov NCT05032807). CBD is approved for treatment-resistant…